MX9701360A - Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion. - Google Patents

Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.

Info

Publication number
MX9701360A
MX9701360A MX9701360A MX9701360A MX9701360A MX 9701360 A MX9701360 A MX 9701360A MX 9701360 A MX9701360 A MX 9701360A MX 9701360 A MX9701360 A MX 9701360A MX 9701360 A MX9701360 A MX 9701360A
Authority
MX
Mexico
Prior art keywords
demyelinating
inhibiting
methods
dysmyelinating diseases
dysmyelinating
Prior art date
Application number
MX9701360A
Other languages
English (en)
Inventor
Andrew Lawrence Glasebrook
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9701360A publication Critical patent/MX9701360A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere al uso de un compuesto que tiene la formula (I) en donde R1 y R2 son, en forma independiente, hidrogeno, -CH3, (a) o (b) en donde Ar es fenilo substituido opcionalmente; R2 se selecciona del grupo que consiste de pirrolidina, haxametilenimino, y piperidino; o una sal o solvato, farmacéuticamente aceptable del mismo, para la preparacion de un medicamento para inhibir las enfermedades de desmielizacion o dismielinizacion o sus síntomas.
MX9701360A 1994-08-22 1995-08-21 Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion. MX9701360A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/294,238 US5434166A (en) 1994-08-22 1994-08-22 Methods of inhibiting demyelinating and desmyelinating diseases
PCT/US1995/010581 WO1996005823A1 (en) 1994-08-22 1995-08-21 Methods of inhibiting demyelinating and dysmyelinating diseases

Publications (1)

Publication Number Publication Date
MX9701360A true MX9701360A (es) 1997-05-31

Family

ID=23132498

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9701360A MX9701360A (es) 1994-08-22 1995-08-21 Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.

Country Status (10)

Country Link
US (2) US5434166A (es)
EP (1) EP0769943A4 (es)
JP (1) JPH10505823A (es)
AU (1) AU3368595A (es)
BR (1) BR9508732A (es)
CA (1) CA2198114A1 (es)
IL (1) IL115015A0 (es)
MX (1) MX9701360A (es)
WO (1) WO1996005823A1 (es)
ZA (1) ZA956993B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6417198B1 (en) 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
ZA982877B (en) * 1997-04-09 1999-10-04 Lilly Co Eli Treatment of central nervous system disorders with selective estrogen receptor modulators.
US6117911A (en) * 1997-04-11 2000-09-12 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US5990129A (en) * 1997-09-23 1999-11-23 Eli Lilly And Company Methods for regulating trkA expression
CA2344717A1 (en) 1998-09-28 2000-04-06 The Johns Hopkins University Adrenoleukodystrophy treatments and drug screening
EP1175433B1 (en) 1999-05-04 2005-08-03 Strakan International Limited Androgen glycosides and androgenic activity thereof
US6458838B1 (en) 1999-09-28 2002-10-01 Johns Hopkins University Adrenoleukodystrophy treatments
US6329564B1 (en) * 1999-11-29 2001-12-11 Michael Lebner Bandage for wound or incision closure
AU2004204675A1 (en) * 2003-01-06 2004-07-29 Wyeth The use of estrogen receptor alpha modulators for the treatment of multiphe sclerosis
WO2011011781A1 (en) 2009-07-24 2011-01-27 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
JP2019524805A (ja) * 2016-08-12 2019-09-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 髄鞘再生療法
BR112019028097A2 (pt) 2017-06-28 2020-07-28 Baylor College Of Medicine terapia combinada para tratar distúrbios do ciclo de ureia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5521198A (en) * 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease

Also Published As

Publication number Publication date
US5434166A (en) 1995-07-18
EP0769943A1 (en) 1997-05-02
JPH10505823A (ja) 1998-06-09
EP0769943A4 (en) 1999-07-07
CA2198114A1 (en) 1996-02-29
AU3368595A (en) 1996-03-14
BR9508732A (pt) 1997-11-11
WO1996005823A1 (en) 1996-02-29
ZA956993B (en) 1997-02-21
US5530010A (en) 1996-06-25
IL115015A0 (en) 1995-12-08

Similar Documents

Publication Publication Date Title
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
HU9403675D0 (en) Methods of inhibiting thrombin
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
AU7578794A (en) Methods for inhibiting endometriosis
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
SG46324A1 (en) Methods of inhibiting uterine fibrosis
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
MX9701333A (es) Metodos para inhibir el daño neuronal.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701359A (es) Metodos para la inhibicion de la hiperplasia endometrial primaria.
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9705537A (es) Metodos y composiciones para inhibir el efecto de los estrogenos del medio ambiente.
MX9702853A (es) Metodos para inhibir condiciones asociadas con el neuropeptido "y".
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9709536A (es) Metodo para reducir el factor de transcripcion bef-1.
MX9702861A (es) Metodo para inhibir las condiciones asociadas con la bradicinina.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9706072A (es) Metodos de inhibicion de la adhesion celula-celula.
MX9706520A (es) Metodos para inhibir el cancer de ovario.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.